YOLFTbeta
Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc.

KLRS · NASDAQ · Healthcare / Biotechnology

1.58USD-0.08 (-5.12%)

Price History

Full chart

Market Stats

Previous Close1.66
Open1.64
Day Range1.55 – 1.70
52-Week Range2.81 – 11.88
Volume41.00K
Market Cap69.51M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.90
Dividend Yield0.00%
50-Day Avg3.80
200-Day Avg6.25

About

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Andrew Oxtoby
  • Employees20
  • Headquarters400 Connell Drive, Berkeley Heights, NJ, United States, 07922, USA
  • Websitehttps://kalaristx.com

Leadership

  • Mr. Andrew OxtobyPresident, CEO & Director · b. 1974
  • Dr. Srinivas Akkaraju M.D., Ph.D.Director & Co-Founder · b. 1968
  • Dr. Michael Philip Dybbs Ph.D.Co-Founder & Director · b. 1975
  • Dr. Napoleone Ferrara M.D.Independent Director & Co-Founder · b. 1957
  • Dr. Matthew Feinsod M.D.Chief Medical Officer · b. 1971
  • Ms. Liisa Ann Bayko M.B.A.CFO & Treasurer · b. 1971
  • Ms. Amy VandekopInterim Principal Accounting Officer & Corporate Controller · b. 1989
  • Ms. Kristine CurtissSenior Vice President of Clinical
  • Dr. Jill E. Porter Ph.D.Senior Vice President of CMC

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.14M165.00K--0000
Growth (%)--85.46%------
Cost of Revenue--73.00K1.12M---13.00K
Gross Profit---73.00K-1.12M----13.00K
Operating Expense--71.24M168.70M---46.14M
Operating Income-3.60M-26.70M-71.31M-169.82M-14.01M-13.46M-55.26M-46.15M
Operating Margin-316.83%-16182.42%------
EBITDA-2.43M-23.82M-69.71M-169.84M-15.25M-14.01M-58.77M-41.98M
EBITDA Margin-214.10%-14436.36%------
Net Income-2.43M-23.84M-69.78M-171.96M-15.48M-14.70M-58.77M-43.44M
Net Income Margin-214.10%-14447.88%------
R&D1.70M16.23M49.59M119.62M11.76M11.71M12.34M30.75M
R&D as % of Total Revenue149.78%9835.76%------
Interest Expense----235.00K687.00K2.70M1.44M

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.32M139.42M370.82M286.59M3.90M3.33M118.55M121.74M
Total Liabilities3.74M17.80M17.76M61.33M34.17M48.35M5.24M42.92M
Total Equity21.58M121.62M353.06M225.27M-30.27M-45.02M113.31M78.81M
Cash24.96M61.08M122.66M201.66M3.06M3.17M118.29M98.05M
Total Debt-11.76M8.69M30.07M3.25M--1.45M
Net Debt-24.96M-49.33M-113.97M-171.59M194.00K-3.17M-118.29M-96.61M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.94M-20.16M-60.81M-106.32M-9.78M-14.13M-67.70M-42.98M
Investing Cash Flow--64.64M-169.50M185.98M--95.00M-19.72M
Financing Cash Flow22.87M120.92M291.98M232.00K12.78M14.24M21.00K159.61M
Capital Expenditure0339.00K235.00K26.00K000200.00K
Free Cash Flow1.94M-20.49M-61.05M-106.34M-9.78M-14.13M-67.70M-43.18M
FCF to OCF100.00%101.68%100.39%100.02%100.00%100.00%100.00%100.47%

Earnings

Report DateJun 3, 2020Jul 6, 2020Nov 10, 2020Feb 11, 2021May 6, 2021Aug 6, 2021Nov 5, 2021Feb 10, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Feb 15, 2023May 4, 2023Aug 3, 2023Nov 2, 2023Feb 8, 2024May 2, 2024Aug 1, 2024Nov 29, 2024Feb 12, 2025May 14, 2025Aug 13, 2025Nov 12, 2025Mar 17, 2026May 12, 2026Aug 11, 2026Nov 11, 2026
EPS Estimate-0.20-4.43-0.58-0.44-0.50-0.60-0.72-0.92-0.69-0.69-0.50-0.32-0.47-0.48-0.39-0.52-0.26-0.05-0.10-0.12-0.77-0.52-0.61-0.55-0.52-0.50-0.51
EPS Actual-4.21-0.34-0.58-0.41-0.50-0.60-0.72-0.92-0.69-0.69-0.50-0.32-0.44-0.48-0.39-0.52-0.26-0.05-0.82-3.28-2.52-0.61-0.64-0.44-0.46-0.48-
Surprise-2005.00%92.33%0.00%6.82%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%6.38%0.00%0.00%0.00%0.00%0.00%-765.58%-2633.33%-227.27%-17.31%-4.92%20.00%11.54%4.00%-
Timing--------------------Pre-marketPre-marketPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap69.51M
Enterprise Value-16.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.31
EPS-1.90
Book Value2.42
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-46.14M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-79.91%
Return on Assets-31.03%
Shares Outstanding23.80M
Shares Float7.25M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 18.71
  • Strong Buy
    2

Ownership Breakdown

Institutions
75.72%
Insiders
8.81%
Retail / Other
15.47%

Top Institutional Holders

  • Samsara BioCapital, LLC
    12.88M54.11%
  • RTW INVESTMENTS, LLC
    1.30M5.46%
  • Alyeska Investment Group, L.P.
    572.69K2.41%
  • Siren, L.L.C.
    435.80K1.83%
  • Ikarian Capital, LLC
    360.00K1.51%
  • Kalehua Capital Management LLC
    271.17K1.14%
  • Vanguard Capital Management, LLC
    255.35K1.07%
  • The Goldman Sachs Group Inc
    110.50K0.46%
  • ADAR1 Capital Management LLC
    100.00K0.42%
  • Woodline Partners LP
    100.00K0.42%
  • WHI TRUST Co LLC
    97.49K0.41%
  • Citadel Advisors Llc
    95.77K0.40%
  • BOOTHBAY FUND MANAGEMENT, LLC
    92.26K0.39%
  • Geode Capital Management, LLC
    87.55K0.37%
  • Verdad Advisers, LP
    80.30K0.34%
  • Marshall Wace Asset Management Ltd
    67.88K0.29%
  • Renaissance Technologies Corp
    66.15K0.28%
  • Susquehanna International Group, LLP
    52.68K0.22%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    255.34K1.07%
  • Fidelity Extended Market Index
    58.88K0.25%

Stock Splits

  • Jan 16, 20251:23